| 引用本文: |
何丹,黄建华,黄小龙,秦优,陈林,朱立华,张水寒.复方菝葜治疗非小细胞肺癌的研究进展[J].湖南中医药大学学报,2018,38(11):1354-1358,封三[点击复制] |
|
| |
|
|
| 本文已被：浏览 2385次 下载 1487次 |
| 复方菝葜治疗非小细胞肺癌的研究进展 |
| 何丹,黄建华,黄小龙,秦优,陈林,朱立华,张水寒 |
| (湖南中医药大学, 湖南 长沙 410208;湖南省中医药研究院, 湖南 长沙 410013;湖南国华制药有限公司, 湖南 长沙 410013) |
| 摘要: |
| 肺癌是发病率和死亡率增长最快，对人群健康和生命威胁最大的恶性肿瘤之一，而非小细胞肺癌（non-small cell lung cancer，NSCLC）约占全部肺癌的80%~90%。单纯的放疗、化疗或手术治疗，在缓解患者痛苦和治疗中晚期患者中效果不佳。近年来采用中药复方或中药复方辅助西医手段治疗NSCLC的研究不断取得新的进展。研究表明，复方菝葜可能通过促进细胞免疫和诱导癌症细胞凋亡的途径治疗NSCLC，表现出改善患者症状、提高生存质量、延长患者生存期的作用。本文对复方菝葜治疗NSCLC的临床、血清药理学及网络药理学试验研究进行综述，旨在阐明其作用效果及机制，为复方菝葜的现代化研究及二次开发提供依据。 |
| 关键词: 复方菝葜 非小细胞肺癌 血清药理学 网络药理学 |
| DOI：10.3969/j.issn.1674-070X.2018.11.030 |
| 投稿时间：2018-04-11 |
| 基金项目:湖南省自然科学基金（2016JJ4055）；湖南省重点研发计划（2016SK2048） |
|
| Research Advances in Compound Rhizoma Smilacis Chinensis in Treatment of Non-small Cell Lung Cancer |
| HE Dan,HUANG Jianhua,HUANG Xiaolong,QIN You,CHEN Lin,ZHU Lihua,ZHANG Shuihan |
| (Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;Hunan Academy of Chinese Medicine, Changsha, Hunan 410013, China;Hunan Guohua Pharmaceutical Co., Ltd., Changsha, Hunan 410013, China) |
| Abstract: |
| Lung cancer is one of the malignant tumors with the fastest increases in morbidity and mortality and the greatest threats to human health and lives. Non-small cell lung cancer (NSCLC) accounts for 80% to 90% of all lung cancers. The efficacy of radiotherapy, chemotherapy, or surgical treatment alone is poor in relieving patients' pain and treating patients with advanced NSCLC. In recent years, a lot of great advances have been made in the studies of traditional Chinese medicine compound alone or as an adjuvant to Western medicine in the treatment of NSCLC. Previous studies have demonstrated that compound Rhizoma Smilacis Chinensis improves symptoms, the quality of life, and survival time of NSCLC patients, probably by promoting cellular immunity and inducing apoptosis of cancer cells. This article reviews the clinical, serum pharmacological, and network pharmacological studies of compound Rhizoma Smilacis Chinensis in the treatment of NSCLC, with the aim of elucidating its therapeutic effects and mechanisms and providing evidence for the modernization and re-development of compound Rhizoma Smilacis Chinensis. |
| Key words: compound Rhizoma Smilacis Chinensis non-small cell lung cancer serum pharmacology network pharmacology |
|
二维码（扫一下试试看！） |
|
|
|
|
